Two phase 2 trials studied the efficacy of fibroblast growth factor receptor (FGFR) inhibitors in intrahepatic cholangiocarcinoma with FGFR2 aberrations and found a median PFS of 5.8 months29 and an ORR of 14.8–21.0%.29,30 Dabrafenib, a BRAF inhibitor, combined with trametinib, a MEK inhibitor, showed an ORR of 41%, a median PFS of 7.2 months and a median OS of 11.3 months in patients with BRAF V600E-mutated BTC previously treated in the first line.31 This evidence concerns the gene MAP2K7 and intrahepatic cholangiocarcinoma.